Show simple item record

Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries

dc.contributor.authorHusa, Petr
dc.contributor.authorLeblebicioglu, Hakan
dc.contributor.authorArends, Joop E.
dc.contributor.authorCorti, Giampaolo
dc.contributor.authorSantos, Lurdes
dc.contributor.authorBoesecke, Christoph
dc.contributor.authorUstianowski, Andrew
dc.contributor.authorDuberg, Ann-Sofi
dc.contributor.authorRuta, Simona
dc.contributor.authorSalkic, Nermin N.
dc.contributor.authorLazarevic, Ivana
dc.contributor.authorPinede, Juan A.
dc.contributor.authorPshenichnaya, Natalia Yurievna
dc.contributor.authorTsertswadze, Tengiz
dc.contributor.authorMaticic, Mojca
dc.contributor.authorPuca, Edmond
dc.contributor.authorAbuova, Gulzhan
dc.contributor.authorGervain, Judit
dc.contributor.authorBayramli, Ramin
dc.contributor.authorAhmeti, Salih
dc.contributor.authorKoulentaki, Mairi
dc.contributor.authorKilani, Badreddine
dc.contributor.authorVince, Adriana
dc.contributor.authorNegro, Francesco
dc.contributor.authorSÜNBÜL, MUSTAFA
dc.contributor.authorSalmon, Dominique
dc.contributor.authorOzaras, Resat
dc.date.accessioned2021-03-03T10:02:44Z
dc.date.available2021-03-03T10:02:44Z
dc.identifier.citationLeblebicioglu H., Arends J. E. , Ozaras R., Corti G., Santos L., Boesecke C., Ustianowski A., Duberg A., Ruta S., Salkic N. N. , et al., "Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries", ANTIVIRAL RESEARCH, cilt.150, ss.9-14, 2018
dc.identifier.issn0166-3542
dc.identifier.othervv_1032021
dc.identifier.otherav_2061f1ee-7122-470f-9b99-ca85a0f3f9ea
dc.identifier.urihttp://hdl.handle.net/20.500.12627/26837
dc.identifier.urihttps://doi.org/10.1016/j.antiviral.2017.12.001
dc.description.abstractBackground. Treatment with direct acting antiviral agents (DAAs) has provided sustained virological response rates in > 95% of patients with chronic hepatitis C virus (HCV) infection. However treatment is costly and market access, reimbursement and governmental restrictions differ among countries. We aimed to analyze these differences among European and Eurasian countries.
dc.language.isoeng
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectMikrobiyoloji ve Klinik Mikrobiyoloji
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectVİROLOJİ
dc.subjectİmmünoloji
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.subjectViroloji
dc.subjectEczacılık
dc.subjectTemel Eczacılık Bilimleri
dc.titleAvailability of hepatitis C diagnostics and therapeutics in European and Eurasia countries
dc.typeMakale
dc.relation.journalANTIVIRAL RESEARCH
dc.contributor.departmentOndokuz Mayıs Üniversitesi , ,
dc.identifier.volume150
dc.identifier.startpage9
dc.identifier.endpage14
dc.contributor.firstauthorID251558


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record